We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
The current MYD market cap is 2.09B. The company's latest EPS is USD -2.9296 and P/E is -8.53.
| Year End December 30 2023 | 2020 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Revenue | 641.4M | 299.8M | 690.6M | 678.4M | 753.2M |
| Operating Income | -231.7M | -87.8M | -190.5M | -140.6M | -257.4M |
| Net Income | -199.5M | -53.1M | -27.2M | -112M | -263.3M |
| Year End December 30 2023 | 2020 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Assets | 1.4B | 1.42B | 1.32B | 1.2B | 1.15B |
| Total Liabilities | 486.4M | 537.8M | 352.9M | 312.9M | 363.3M |
| Total Equity | 918.2M | 881M | 967.8M | 885.8M | 783.2M |
| Year End December 30 2023 | 2020 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Operating | 60.7M | -73.7M | 18.2M | -106.3M | -110.9M |
| Investing | 19.3M | 28M | 274.4M | -77.5M | 31.9M |
| Financing | -10M | -2.1M | -150.6M | -8M | 152.9M |
| Market Cap | 2.09B |
| Price to Earnings Ratio | -8.53 |
| Price to Sales Ratio | 2.98 |
| Price to Cash Ratio | 17 |
| Price to Book Ratio | 2.87 |
| Dividend Yield | - |
| Shares Outstanding | 89.87M |
| Average Volume (1 week) | 50 |
| Average Volume (1 Month) | 188 |
| 52 Week Change | 45.00% |
| 52 Week High | 23.40 |
| 52 Week Low | 13.20 |
| Spread (Intraday) | 0.2 (0.86%) |
| Company Name | Myriad Genetics Dl 01 |
| Address |
corporation trust center wilmington, delaware 19801 |
| Website | https://www.myriad.com |
| Industry | in vitro,in vivo diagnostics (2835) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
